Telomir Pharmaceuticals, Inc. Common Stock (TELO) — Cash Flow-to-Debt Ratio
Latest as of March 2026:
-2.14x
Telomir Pharmaceuticals, Inc. Common Stock (TELO) has a Cash Flow-to-Debt Ratio of -2.14x as of March 2026, meaning its operating cash flow of $-1.77 Million could theoretically repay -2% of its total liabilities ($827.31K) in one year. See TELO financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-2.14x
Operating CF / Total Liabilities
Operating Cash Flow
$-1.77 Million
USD
Total Liabilities
$827.31K
USD
Data as of
Mar 2026
Most recent filing
Telomir Pharmaceuticals, Inc. Common Stock Cash Flow-to-Debt Ratio (2021–2025)
Historical debt coverage capacity for Telomir Pharmaceuticals, Inc. Common Stock across 5 annual periods. For the full cash flow conversion analysis, see TELO cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Telomir Pharmaceuticals, Inc. Common Stock (2021–2025)
Year-by-year debt coverage analysis for Telomir Pharmaceuticals, Inc. Common Stock.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.58x | $-3.69 Million | $1.43 Million | ▲ +65.3% |
| 2024 | -7.45x | $-5.07 Million | $680.97K | ▼ -157.6% |
| 2023 | -2.89x | $-3.86 Million | $1.34 Million | ▼ -508.0% |
| 2022 | -0.48x | $-468.66K | $986.01K | ▲ +45.0% |
| 2021 | -0.86x | $-119.40K | $138.13K | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.